22nd Century to Participate in the Emerging Growth Conference on December 10, 2025

22nd Century Group (Nasdaq: XXII) announced that CEO Larry Firestone will present at the Emerging Growth Virtual Investor Conference on Wednesday, December 10, 2025 at 3:55 PM ET.

Rhea-AI Summary

22nd Century Group (Nasdaq: XXII) announced that CEO Larry Firestone will present at the Emerging Growth Virtual Investor Conference on Wednesday, December 10, 2025 at 3:55 PM ET.

Investors can register to attend the live webcast and submit questions in advance; an archived webcast will be posted in the Events section of the company's investor relations website if attendees cannot join live.

Background: 22nd Century develops proprietary non‑GMO reduced‑nicotine tobacco (reported as 95% less nicotine vs traditional tobacco) and markets the FDA‑authorized VLN® combustible cigarette.

Argus Dec 9 session

-2.68% close to close Open Argus

Details

News Market Reaction – XXII

On Dec 9, the day this news came out, XXII closed 2.68% below the previous close.

Data tracked by StockTitan Argus for the Dec 9 session.

Market Context

This announcement highlighted 22nd Century’s participation in an investor conference, offering manag...

Analysis

This announcement highlighted 22nd Century’s participation in an investor conference, offering management a platform to reiterate its VLN® strategy and FDA authorization. Context from recent filings showed shrinking Q3 revenue of $4.0 million, going concern language, and reliance on tools like a $25,000,000 ATM and an effective resale shelf. Investors following this story typically watched liquidity, execution of VLN® distribution, and any further use of registered equity capacity.

Key Figures

ATM offering size: $25,000,000 Q3 2025 revenue: $4.0 million Q3 2025 operating loss: $3.2 million +5 more

ATM offering size

$25,000,000

At-the-market common stock program via 424B5 on 11/04/2025

Q3 2025 revenue

$4.0 million

Quarterly revenue vs $5.9 million a year ago per 10-Q

Q3 2025 operating loss

$3.2 million

Operating loss from continuing operations per 10-Q

Q3 2025 net income

$5.5 million

Net income driven by $9.3 million from discontinued operations

Quarter-end cash

$4.8 million

Cash balance at Q3 2025 with going concern uncertainty noted

Insurance settlement

$9.5 million

Business interruption settlement related to Grass Valley incident

Nicotine reduction

95% less nicotine

VLN tobacco vs traditional cigarettes in company products

Prevented new smokers

48 million youth/young adults

FDA model estimate tied to reduced nicotine mandate

Historical Context

5 past events · Latest: Oct 28

5 events

1. Oct 28

   Insurance cash receipt

   24h Move

   -0.7%

   Receipt of $9.5M insurance proceeds supporting balance sheet and VLN focus.

2. Oct 23

   Product rollout news

   24h Move

   +3.4%

   VLN rollout into ~140 Circle K stores and broader state authorizations.

3. Oct 21

   Earnings date notice

   24h Move

   -1.9%

   Announcement of upcoming Q3 2025 results release and webcast timing.

4. Sep 30

   Regulatory comment

   24h Move

   +3.7%

   Supportive FDA comments on reduced nicotine mandate and VLNC technology.

5. Sep 24

   Insurance settlement

   24h Move

   -4.4%

   $9.5M settlement, debt-free status, and profitability goal for 2026.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-gmo, biosynthesis, fda

3 terms

non-gmo medical

"Our proprietary non-GMO reduced nicotine tobacco plants were developed"

Non-GMO means a product or ingredient was produced without genetic modification techniques — the plant or organism’s DNA has not been intentionally altered in a laboratory. Investors care because non-GMO labeling can affect consumer demand, price premiums, shelf access and supply-chain cost; think of it like an organic or “no added hormones” label that can open certain markets, change margins, and create reputational risk or advantage for companies.

biosynthesis medical

"technologies that regulate alkaloid biosynthesis activities resulting in a tobacco plant"

Biosynthesis is the natural process cells use to build complex molecules from simpler building blocks, like a microscopic factory assembling parts into finished products such as proteins, fats or small drug-like compounds. For investors, biosynthesis matters because how efficiently and reliably a company can make a desired molecule affects production cost, scalability, regulatory risk and competitive advantage—similar to how a better assembly line lowers manufacturing costs and boosts output.

fda regulatory

"VLN® cigarette is the only low nicotine combustible cigarette authorized by the FDA"

The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MOCKSVILLE, N.C., Dec. 09, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced that Larry Firestone, Chief Executive Officer, will present as part of the Emerging Growth Virtual Investor Conference taking place on Wednesday, December 10, 2025. The Company’s update presentation will take place at 3:55 PM Eastern Time.

Investors can register to attend online at: https://goto.webcasts.com/starthere.jsp?ei=1717093&tp_key=e9cb5d164a&sti=xxii. Investors may submit questions in advance to Questions@EmergingGrowth.com for consideration as part of the webcast event, time permitting.

If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available in the Events section on 22nd Century’s Investor Relations website at https://ir.xxiicentury.com/events.

About 22^nd Century Group, Inc.

22nd Century Group is pioneering the tobacco harm reduction movement by enabling smokers to take control of their nicotine consumption.

Our Technology is Tobacco

Our proprietary non-GMO reduced nicotine tobacco plants were developed using our patented technologies that regulate alkaloid biosynthesis activities resulting in a tobacco plant that contains 95% less nicotine than traditional tobacco plants. Our extensive patent portfolio has been developed to ensure that our high-quality tobacco can be grown commercially at scale. We continue to develop our intellectual property to ensure our ongoing leadership in the tobacco harm reduction movement.

Our Products
We created our flagship product, the VLN^® cigarette using our low nicotine tobacco, to give traditional cigarette smokers an authentic and familiar alternative in the form of a combustible cigarette that helps them take control of their nicotine consumption. VLN^® cigarettes have 95% less nicotine compared to traditional cigarettes and have been proven to allow consumers to greatly reduce their nicotine consumption.

FDA Authorized
Our VLN^® cigarette is the only low nicotine combustible cigarette authorized by the FDA in the United States.
VLN^® is a registered trademark of 22nd Century Limited LLC.

Learn more at xxiicentury.com, on X (formerly Twitter), on LinkedIn, and on YouTube.
Learn more about VLN^® at tryvln.com.

Cautionary Note Regarding Forward-Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements, including but not limited to our full year business outlook. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Forward-looking statements include, but are not limited to, statements regarding (i) our cost reduction initiatives, (ii) our expectations regarding regulatory enforcement, including our ability to receive an exemption from new regulations, and (iii) our financial and operating performance. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s Annual Report on Form 10-K filed on March 20, 2025 and Quarterly Reports on Form 10-Q on May 13, 2025, August 14, 2025, and November 4, 2025. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

Investor Relations & Media Contact
Matt Kreps
Investor Relations
22nd Century Group
investorrelations@xxiicentury.com
214-597-8200

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will 22nd Century (XXII) present at the Emerging Growth Conference?

CEO Larry Firestone will present on December 10, 2025 at 3:55 PM ET.

How can investors register for the 22nd Century (XXII) webcast on December 10, 2025?

Investors can register via the conference webcast registration link provided by the event organizer.

Will the 22nd Century (XXII) presentation be available after the live event?

Yes. An archived webcast will be posted in the Events section of 22nd Century's investor relations website.

What product and regulatory status does 22nd Century (XXII) highlight in investor materials?

The company highlights its VLN® combustible cigarette, which it states is the only low‑nicotine combustible cigarette authorized by the FDA in the United States.

What does 22nd Century (XXII) mean by reduced‑nicotine tobacco?

The company describes its proprietary non‑GMO tobacco as containing 95% less nicotine compared with traditional tobacco plants.